StockNews.com Downgrades Natera (NASDAQ:NTRA) to Sell

Natera (NASDAQ:NTRA) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday.

Several other research analysts also recently issued reports on NTRA. Canaccord Genuity Group raised their price objective on shares of Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, February 29th. BTIG Research lifted their target price on shares of Natera from $75.00 to $85.00 and gave the company a “buy” rating in a report on Friday, December 29th. Piper Sandler lifted their target price on shares of Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 target price on the stock in a report on Friday, April 5th. Finally, Craig Hallum started coverage on shares of Natera in a report on Monday, April 8th. They issued a “buy” rating and a $117.00 target price on the stock. One investment analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat, Natera has a consensus rating of “Moderate Buy” and an average price target of $86.40.

Natera Trading Up 0.5 %

Shares of Natera stock opened at $91.50 on Tuesday. Natera has a 1 year low of $36.90 and a 1 year high of $98.82. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.96 and a current ratio of 4.10. The company has a market capitalization of $11.05 billion, a P/E ratio of -24.29 and a beta of 1.37. The company’s fifty day moving average is $86.85 and its two-hundred day moving average is $66.82.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.09. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. The company had revenue of $311.11 million for the quarter, compared to the consensus estimate of $300.38 million. Analysts forecast that Natera will post -2.35 earnings per share for the current year.

Insider Activity at Natera

In related news, insider Jonathan Sheena sold 447 shares of the firm’s stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $90.22, for a total value of $40,328.34. Following the completion of the sale, the insider now owns 347,731 shares in the company, valued at $31,372,290.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Natera news, insider John Fesko sold 2,358 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $65.09, for a total value of $153,482.22. Following the sale, the insider now owns 108,494 shares of the company’s stock, valued at $7,061,874.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jonathan Sheena sold 447 shares of the company’s stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $90.22, for a total transaction of $40,328.34. Following the completion of the sale, the insider now directly owns 347,731 shares in the company, valued at approximately $31,372,290.82. The disclosure for this sale can be found here. Insiders sold 453,644 shares of company stock worth $36,594,940 over the last 90 days. Company insiders own 9.42% of the company’s stock.

Institutional Trading of Natera

Institutional investors and hedge funds have recently modified their holdings of the business. RiverPark Advisors LLC purchased a new stake in shares of Natera in the fourth quarter valued at about $27,000. Principal Securities Inc. purchased a new position in shares of Natera during the fourth quarter valued at approximately $32,000. Harvest Fund Management Co. Ltd purchased a new position in shares of Natera during the third quarter valued at approximately $44,000. Oliver Lagore Vanvalin Investment Group lifted its stake in shares of Natera by 109.3% during the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after buying an additional 389 shares during the period. Finally, Arcadia Investment Management Corp MI lifted its stake in shares of Natera by 47.8% during the first quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock valued at $49,000 after buying an additional 174 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.